3SBio Inc
HKEX:1530

Watchlist Manager
3SBio Inc Logo
3SBio Inc
HKEX:1530
Watchlist
Price: 25.66 HKD -2.21% Market Closed
Market Cap: 62.4B HKD

Operating Margin
3SBio Inc

27.4%
Current
29%
Average
-4.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
27.4%
=
Operating Profit
2.5B
/
Revenue
9.1B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
CN
3SBio Inc
HKEX:1530
60.5B HKD
27%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
395.1B USD
33%
US
Amgen Inc
NASDAQ:AMGN
174.1B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
148.5B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.4B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.7B USD
28%
AU
CSL Ltd
ASX:CSL
85.8B AUD
26%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.5B USD
8%
NL
argenx SE
XBRU:ARGX
44.3B EUR
22%
No Stocks Found

3SBio Inc
Glance View

Market Cap
60.5B HKD
Industry
Biotechnology

3SBio Inc., founded in 1993, is a prominent player in the biopharmaceutical landscape of China. Driven by a mission to improve human health quality through biopharmaceutical innovation, the company has cultivated a robust portfolio of products, primarily focusing on three key therapeutic areas: oncology, nephrology, and autoimmune diseases. At the core of 3SBio's operations is its strong emphasis on research and development, with several state-of-the-art facilities where it continuously explores advancements in biological medicines. These efforts have positioned the company as a leader in the production of recombinant proteins and antibodies, which are essential in treating chronic and life-threatening conditions. 3SBio derives its revenue through a well-integrated business model that spans drug development, manufacturing, and commercialization. This model allows the company not only to generate income from its diverse product offerings but also to leverage strategic partnerships and licensing agreements, both locally and internationally. Their flagship products, such as EPIAO, a recombinant human erythropoietin used to treat anemia associated with chronic kidney disease, and TPIAO, a thrombopoietin receptor agonist used in the management of idiopathic thrombocytopenic purpura, are among the top revenue drivers. By maintaining a strong pipeline of both innovative and biosimilar products, 3SBio ensures sustained profitability and growth, meeting the ever-evolving demands of healthcare systems and patients worldwide. Amidst the competitive and rapidly evolving biotech industry, 3SBio stands out with its commitment to quality and innovation, anchored by a strategic vision to expand its influence beyond traditional boundaries.

Intrinsic Value
19.58 HKD
Overvaluation 24%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
27.4%
=
Operating Profit
2.5B
/
Revenue
9.1B
What is the Operating Margin of 3SBio Inc?

Based on 3SBio Inc's most recent financial statements, the company has Operating Margin of 27.4%.

Back to Top